[Treatment of hepatitis C: advances and consensus].
E
E
Lerebours
P
P
Marcellin
D
D
Dhumeaux
D000368:Aged; D000437:Alcoholism / Q000150:complications; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000209:etiology; D003245:Consensus Statements as Topic; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000150:complications; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology; D008297:Male; D010297:Paris; D012106:Research; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D019966:Substance-Related Disorders / Q000150:complications
D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons